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A B S T R A C T
Vulvar squamous cell carcinoma associated with lichen sclerosus (VLS-VSCC) are rare tumors but with higher
recurrence and worse prognosis than other types of VSCC. Lack of experimental models has limited the search for
better understanding of the biology and development of treatment modalities. In this study, we isolated and
characterized primary cells from VSCC (n= 7) and normal vulvar tissue adjacent to tumor (n= 7). Detailed
characterization of the novel spontaneously immortalized cell line, VCC1 revealed a characteristic epithelial
morphology in vitro and a well-differentiated keratinizing SCC histology in vivo, closely resembling the tumor of
origin. VCC1 expressed higher levels of epithelial-mesenchymal transition markers and higher clonogenic
properties as compared to other established non VLS-VSCC cell lines. In vitro 3D organotypic assays and in vivo
xenografts revealed a prominent role of cancer-associated fibroblasts in VCC1 invasion and tumor formation. In
conclusion, VCC1 mirrored several major VLS-VSCC features and provided a robust experimental tool for further
elucidation of VLS-related oncogenesis and drug testing.
1. Introduction
With an incidence of 0.5–1.5 in 100,000 individuals per year, car-
cinoma of the vulva represents about 4% of all female genital cancers
[1]. Of these, nearly 90% of cases are squamous cell carcinomas
(VSCC). It is well documented that VSCC develops from premalignant
vulvar intraepithelial neoplasia (VIN) lesions [2,3]. Previously, VIN was
graded into three subtypes: VIN 1 (mild dysplasia), VIN 2 (moderate
dysplasia) and VIN 3 (severe dysplasia). However, clinico-pathological
data did not support the presence of such continuum [4]. According to
the latest and widely accepted grading system, the previously used VIN
terminology has been replaced by cytology-based squamous in-
traepithelial lesions (SIL) terminology [5,6]. Consequently, these pre-
cancerous lesions are divided into three types: low-grade squamous
intraepithelial lesions (LSIL, VIN1); high-grade intraepithelial lesions
(HSIL, VIN 2,3 or usual VIN) and a very differentiated variant, called
dVIN. Such grading systems correlates with the risk to cancer pro-
gression over time [6].
In addition, mounting evidence suggests that there are two different
pathological pathways governing the development of VSCC: human
papillomavirus (HPV) -independent and HPV-dependent [6]. HPV-de-
pendent VSCC show a more profound cellular atypia and are histolo-
gically warty/basaloid [6]. These are more common in younger women
and have HSIL as their precursors [6]. On the other hand, HPV-in-
dependent VSCC show basal atypia and often presents a more kerati-
nized histology [6,7]. These typically occur in elderly women, develop
on dVIN background and have a high malignant potential [8]. More-
over, these are often associated with inflammatory conditions such as
vulvar lichen sclerosus (VLS) [3], a chronic inflammatory dermatitis
[9]. Histologically, VLS exhibits a thinned epithelium with hyper-
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keratinization, a band of hyalinized collagen lacking vessels and a
lymphocytic infiltrate beneath [10]. An association between VLS and
VSCC is well-documented [3]. Although the risk for these lesions to
progress to VSCC is low (3–7%) [3,11], approximately 30–60% of
vulvar SCC occur on a VLS background that often is undiagnosed due to
lack of serious clinical symptoms [3,10,12].
There is a dearth of knowledge about the key molecular events in-
volved in vulva cancer in general and VLS-VSCC in particular, which
can be used as predictive markers or as therapeutic targets. In addition,
the role of stromal component of the tumor microenvironment (TME),
especially carcinoma-associated fibroblasts (CAFs) in VLS-VSCC is un-
known. This is due to the lack of well-established experimental models.
Better understanding of this cancer is required at the genetic, mole-
cular, and cellular level. The aim of this study was to establish and
characterize robust experimental models for studying VLS-VSCC. To the
best of our knowledge, this is the first successful attempt to establish a
cell line from VLS-VSCC. We describe here 3D collagen co-culture
models for studying tumor-stroma crosstalk and in vivo xenografts in
immunodeficient mice using this cancer cell line and vulvar CAFs. This
study provides a thorough in vitro and in vivo characterization and va-
lidation of a human-tissue based biological tool relevant for further
studies on VLS-VSCC.
2. Materials and methods
2.1. Sample collection and patient history
Human VSCC tissues (n=7) along with their respective non-cancer
adjacent tissues (normal epithelial tissue, 1 cm away from the tumor
margin showing no histological signs of atypia) were collected from
patients undergoing surgical resection at the Department of Obstetrics
and Gynecology, Haukeland University Hospital, Bergen, Norway.
Written informed consent was obtained from all patients and the
Regional (REK Vest, Norway) Committee for Medical and Health
Research Ethics (REK nr. 2017/279) approved the study. The samples
were included in Bergen Gynecologic Cancer Biobank, Bergen, Norway
(REK nr. 2014/1907). Isolation of vulva cancer cells (VCC) and mat-
ched vulva cancer-associated fibroblasts (VCAF) was successful in 57%
(n=4/7) and 100% (n=7/7) cases, respectively. Besides, normal
vulvar keratinocytes (NVK, n= 5/7, 71%) and normal vulvar fibro-
blasts (NVF, n= 7/7, 100%) from normal adjacent tissue were also
isolated successfully. Out of the four primary cancer cell lines isolated,
only one could be propagated indefinitely without implementing ad-
ditional genetic alterations. This cell line, VCC1 was established from a
VSCC of an 84-year old woman who presented with a 4 cm tumor in
size. Histopathological examination of the whole specimen, including
surrounding tissue was compatible with a HPV negative, VLS associated
keratinizing type VSCC, FIGO stage 1B. The patient is still alive without
recurrence 22 months after the primary surgery.
2.2. Isolation of normal primary keratinocytes and fibroblasts
Primary keratinocytes and fibroblasts were isolated from apparent
normal adjacent tissue to tumor by enzyme digestion. These tissue
samples were incubated in 2.5mg/ml dispase (GIBCO, Paisley, UK)
overnight at 4 °C. The following day, epithelium was detached from the
underlying stroma, minced into small pieces, and treated with 0.5%
trypsin (GIBCO, Paisley, UK) for 5min at 37 °C. Further, the pieces were
neutralized with New-Born Calf Serum (NBCS, GIBCO, Auckland, NZ),
and mechanically dissociated using Pasteur pipettes. The single cell
suspension thus formed was plated in a 6-well plate (Sarstedt,
Nümbrecht, DE) in keratinocyte serum-free medium (KSFM, GIBCO,
Paisley, UK) in a humidifying chamber in 5% CO2 at 37 °C (standard
culture conditions). Similarly, for the fibroblast isolation, the under-
lying stroma left after detachment of the epithelium was cut into
smaller pieces and treated with 1mg/ml collagenase (GIBCO, Paisley,
UK) for 30min at 37 °C. Following neutralization with NBCS, the cells
were cultured in Dulbecco's Modified Eagle's medium (DMEM, Sigma-
Aldrich, St. Louis, US) supplemented with 10% NBCS (DMEM complete)
under standard culture conditions. Adherents cells were first observed
after four days, and keratinocytes-like and fibroblasts-like cell lines
were sub-cultured after nine days in their respective media.
2.3. Isolation of VCC and VCAF from tumor tissue by explant culture
method
The tumor tissue was cut in small pieces (1–2mm2) and allowed to
adhere on several culture plates. After attachment, the plates were
flooded with DMEM complete medium and cultured further. Initial
outgrowth of both VCC and matched VCAF was observed after four
days. The plates containing majority of explants with epithelial-like cell
outgrowth were marked as VCC and explants with outgrowth of fibro-
blast-like morphology were scrapped-off and vice versa for VCAFs.
Further, to clean the cancer cells of fibroblast-like cells and vice-versa,
selective trypsinization (3min for VCAF and 7min for VCC) was done on
9th day. This was followed by serial dilution of VCC in 48 well-plate
(Sarstedt, Nümbrecht, DE). After 4–6 days, the morphology of growing
cells was assessed and wells with only epithelial-like morphology were
selected for further propagation. In case of VCC1, only 6 wells out of 48
had pure epithelial-like morphology. These were mixed and cultured
together to avoid selecting single clonal population. The growth media
used was FAD [13]. For VCAF, 3min trypsinized cells were sub-cultured
in DMEM complete. UMSCV1A and UMSCV4, well-established vulva
cancer cell from non-VLS patients were purchased from Thomas Carey,
University of Michigan, US for comparative studies [14]. All cell lines
were routinely checked for mycoplasma contamination by using My-
coAlert mycoplasma kit (LONZA, Rockland, US) and tested negative.
2.4. Flow cytometry
Expression of lineage-specific markers was assessed by flow cyto-
metry (BD Accuri C6 cytometer, Ann Arbor, US). Cells were trypsinized
and stained with antibodies listed in Table S1. Isotype control mouse
IgG1-APC and IgG1-PE were used for normalization. 30,000 cells were
collected for analysis and cell debris were excluded by gating. Expres-
sion of each antigen was analyzed by FlowJo v10 software (FlowJo LLC,
Ashland, US).
2.5. Growth kinetics and cell cycle analysis
The population doubling time (PDT) was determined by cell viabi-
lity assay based on trypan blue dye exclusion principle. Number of cells
was counted every 24hr in an automated counting chamber (TC20-
Biorad, Hercules, US). The doubling time was calculated using standard
formula mentioned elsewhere [15]. For cell cycle analysis, VCC1 were
grown in serum-deprived medium for 48hr and then harvested at reg-
ular intervals up to 30hr. For harvesting, cells were trypsinized, washed
with PBS, fixed in 2mL ice-cold 70% ethanol and stained for 30min at
room temperature (RT) in dark with 0.025mg/mL propidium iodide
(PI), 0.1% Triton X-100 and 0.05mg/mL ribonuclease A (all from
Sigma-Aldrich, St. Louis, US) in PBS. Total PI content was determined
by Accuri C6 flow-cytometer and cell cycle distribution was quantitated
by ModFit LT software (Verity, Maine, US).
2.6. DNA extraction and short tandem repeats (STR) profiling
Ten-micron thick sections were cut from formalin fixed paraffin
embedded (FFPE) tissue block of the original tumor. Genomic DNA
(gDNA) was extracted from the tumor tissue and cell lines (VCC1 and
VCAF1) using Nucleopsin DNA FFPE kit (Macherey-Nagel GmbH,
Germany) and E.Z.N.A FFPE DNA kit (Omega Bio-Tek Inc., Norcross,
US) respectively, according to manufacturer's protocol. Further,
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AmpFlSTR® Profiler Plus amplification kit (Applied biosystems [AB],
Carlsbad, US) was used to detect nine tetranucleotide STR loci and the
Amelogenin gender-determining marker in a single PCR amplification
tube (Table S2). Amplification by polymerase chain reaction (PCR) was
carried out in AB 2720 Thermal cycler (AB, Carlsbad, US). After PCR
amplification, the products were separated and analyzed using capillary
electrophoresis on an ABI 3500XL genetic analyzer (AB, Carlsbad, US).
2.7. Colony and sphere formation assays
Colony and sphere formation assays were performed following a
protocol mentioned elsewhere [16]. Three independent experiments
were performed for each cell line. Representative images for both as-
says were acquired on DM IRB inverted microscope (Leica, Houston,
US).
2.8. Hr-HPV DNA and gene expression analysis
Total RNA was extracted from cells using RNeasy Mini kit (Qiagen,
Oslo, NO). Following manufacturer's protocol, 300 ng of total RNA was
converted to cDNA using High-Capacity cDNA Kit system (AB, Carlsbad,
US). For tumor tissue, gDNA isolated previously from the tumor FFPE
block was used. Hr-HPV16 E6/E7 DNA was detected using quantitative
reverse transcription PCR (RT-qPCR) following manufacturer's protocol
using SYBR green primers (Table S3). Absence of non-specific amplifi-
cations was confirmed by running the PCR products on agarose gel with
ethidium bromide. UMSCV6, a known HPV16 E6/E7 positive cell line
was used as positive control [14]. For gene expression analysis, all RT-
qPCR amplifications were performed for 40 cycles using AB 7500 PCR
system (AB, Carlsbad, US) for TaqMan probes mentioned in Table S3.
The expression levels of all genes were normalized to GAPDH and the
fold changes generated by 2−ΔΔCt method were plotted as heatmap.
2.9. 3D organotypic co-culture (3D OTC) models
3D OTC were engineered by growing cancer cells on top of collagen
type I (Corning, Bedford, US) matrix populated with and without fi-
broblasts using a protocol well-established in our laboratory [13].
These were cultured in serum-free DMEM with 50 μg/ml L-ascorbic
acid, 0.4 μg/ml hydrocortisone, 5 μg/ml insulin, 20 μg/ml transferrin
and 7.5% bovine serum albumin (all from Sigma, St. Louis, US) for 3
days. On the 4th day, the cultures were lifted at air–liquid interface and
cultured further for 9 days in the same medium. On 13th day, they were
harvested, fixed in formalin and embedded in paraffin for histological
and immunohistochemical staining.
2.10. Immunohistochemistry and immunofluorescence
Immunohistochemical staining was performed using EnVision
+ Detection Systems, Peroxidase/DAB, Rabbit/Mouse (Agilent Dako,
Golstrup, DK) according to standard protocol [17]. Details of primary
antibody dilution and epitope retrieval buffers used are listed in Table
S1. Images were acquired using a whole slide scanner (Hamamatsu
NanoZoomer-XR, Japan).
For immunofluorescence, cells grown on coverslips were fixed with
4% paraformaldehyde for 15min and incubated with primary anti-
bodies (Table S1) for 1 h at RT. Following PBS washes, cells were in-
cubated with Alexa Fluor 488 anti-mouse secondary antibody for 1 h at
RT, counterstained with 4', 6-diamidino- 2-phenylindole (DAPI, Sigma-
Aldrich, Oslo, NO), mounted and viewed under a fluorescence micro-
scope (Axio Imager Z2, Carl Zeiss, DE).
2.11. Quantification of depth of invasion and number of invading cells
Depth of invasion and number of invading VCC1 was measured on
anti pan-cytokeratin immunostained tissue sections using a standard
protocol mentioned elsewhere [18]. For the measurement, 3D OTC
constructed with (NVF1 and VCAF1) and without fibroblasts were used.
2.12. In vivo tumorigenic assay
Four to five week old thirty-six NOD/SCID IIγ2R deficient female
mice were obtained from Jackson Laboratories (Bar Harbor, ME, US)
[19]. The mice were divided randomly in two groups with one group
receiving cells resuspended in PBS in a total injection volume of 100 μL
alone (n= 18) or in a 1:1 mixture of PBS and matrigel (n= 18). Fur-
ther, these groups were subdivided equally, and the mice were injected
subcutaneously with logarithmically growing 1×106 VCC1, alone
(n= 9) or with 1× 105 VCAF1 (ratio 1:10, n=9). Animals were ex-
amined twice per week for 7 weeks for the development of tumors.
Tumor volume was calculated as: volume, V (in mm3) = (LXW2)/2,
where L is tumor length and W is tumor width. Mice with tumors were
sacrificed after 7 weeks. The excised tumors were fixed in 10% formalin
and further processed for histopathology. This study was approved by
the ethical board (S15195) and carried out at the Animal Research
Facility at University of California, San Diego, US.
3. Results
3.1. A novel VLS-VSCC cell line
A cell line was successfully established in vitro from a surgically
resected primary VLS-VSCC tumor. The established cell line has been
successfully frozen, resuscitated and cultured in FAD medium for more
than 21 months (220 PDs). In monolayer culture, VCC1 grew mainly in
tight clusters of polygonal cells as adherent colonies with epithelial
morphology (Fig. 1A a-d). The isolated matched VCAF1, displayed a
characteristically fibroblast-like, spindle-shaped morphology and grew
as loose cells (Fig. 1A e-h). Immunofluorescent staining of VCC1
showed cytokeratin 10 (CK10) staining and weak vimentin staining
(Fig. 1Ba, b). In contrast, VCAF1 were negative for CK10 and positive
for vimentin (Fig. 1B c, d). In addition to this, VCC1 expressed pan-
cytokeratin (AE1/3), CK8, CK18, and stem cell markers such as ALDH1,
CD44 and Oct 3/4 (Fig. S1 A).
As indicated by flow cytometry, majority of VCC1 expressed epi-
thelial cell-adhesion molecule, EpCAM; however, a subpopulation
(< 2%) of cells expressed both EpCAM and mesenchymal lineage spe-
cific cell surface antigen, beta-type platelet-derived growth factor re-
ceptor (PDGFR-β, CD140b). Moreover, the cells also expressed CD146
(~6%), a marker of pericytes and mesenchymal stem cells [20]. Con-
trary to this, majority of VCAF1 expressed CD140b but not EpCAM or
CD146 (Fig. 1C). Neither VCC1 nor VCAF1 (< 1%) expressed CD31, an
endothelial cell marker (Fig. 1C).
3.2. STR profiling validates authenticity of VCC1
In order to rule out cross-contamination with other cell lines and to
confirm the authenticity of isolated cell lines, VCC1 and VCAF1 were
subjected to STR DNA profiling against the original tumor tissue. Out of
9 markers and Amelogenin gender-determining marker tested, both the
VCC1 and VCAF1 expressed all but one marker (≥80% match, meeting
the acceptance criteria) confirming authenticity of the cell lines (Table
S2).
3.3. VCC1 is more clonogenic than non VLS-VSCC cell lines
The colony-forming ability of VCC1 was compared against NVK and
VSCC cell lines from non-VLS patients, UMSCV1A and UMSCV4.
UMSCV1A is known to exhibit a biologically aggressive behavior in
vivo, whereas UMSCV4 displays a more passive behavior [14,21]. VCC1
formed significantly more colonies in vitro than UMSCV1A and
UMSCV4, suggesting a higher clonogenic and proliferative potential
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Fig. 1. Isolation and characterization of vulva cancer cells (VCC1) and vulva cancer-associated fibroblasts (VCAF1). A) Representative phase contrast images showing
outgrowth of cancer cells and fibroblasts at day 4 (a, e), day 6 (b, f) and day 9 (c, g) respectively. Morphology of VCC1 is mainly polygonal (d) whereas VCAF1 were
more spindle-shaped and formed loose cell aggregates (h). Scale bar- 50 μm. B) Immunofluorescence staining showed cytokeratin 10 (CK10, green, a) positive cancer
cells and sparsely positive cells for vimentin (green, b). In case of fibroblasts, no staining for CK10 was detected whereas it was positive for vimentin (green, c and d).
Nuclei are counterstained with DAPI (blue). Scale bar- 100 μm. C) Comparison of expression of EpCAM, CD140b, CD146 and CD31 in between VCAF1 and VCC1
using flow cytometry. Flow cytometry results are expressed as mean ± SD of three independent experiments. (For interpretation of the references to colour in this
figure legend, the reader is referred to the Web version of this article.)
Fig. 2. VCC1 is more clonogenic in comparison to UMSCV1A and UMSCV4. A) Representative micrographs of adherent colonies from NVK6, VCC1, UMSCV1A and
UMSCV4. B) Quantification of adherent colony-formation assay. The number of colonies was counted manually after staining with crystal violet. VCC1 formed
statistically more number of colonies than UMSCV1A and UMSCV4. C) Representative images of formed tumor-spheres. D) Quantification of the sphere formation
assay. The spheres were counted using a stereo microscope at X100 magnification. VCC1 formed more number of spheres than UMSCV1A and UMSCV4. Note that
NVK did not form colonies or spheres and thereby they were excluded from the statistical analysis. Experimental data is expressed as mean ± SD of three
independent experiments and analyzed using Students t-test. **p < 0.01 and ***p = 000.1. (For interpretation of the references to colour in this figure legend, the
reader is referred to the Web version of this article.)
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(Fig. 2 A, B). Also, VCC1 formed statistically significant more spheres
than UMSCV4 and comparable to but bigger in size than UMSCV1A
(Fig. 2 C, D).
3.4. Growth characteristics of VCC1 in vitro and in vivo
PDT of VCC1 at different passages revealed an average doubling
time of 18.90 ± 0.53hr. This was however less than that of UMSCV1A
(30.12 ± 0.43hr) and UMSCV4 (54.7 ± 5.27hr) (Fig. S1 B). Flow
cytometry analysis of PI stained VCC1 illustrated cell cycle distribution
in different stages at different time points (Fig. S1 C). In vivo tumor-
igenicity showed no tumor formation in mice group receiving cells in
PBS only. Interestingly, tumor formation was observed after 4 days of
injection of VCC1 in combination with VCAF1 resuspended in matrigel
(9/9, take rate 100%). The tumor growth was rapid for the first ten days
followed by a decrease in tumor volume afterwards. For VCC1 alone in
matrigel, the take rate was 33% (2/6) and the tumors were small in size
(Fig. S2 A).
3.5. Genetic make-up of VCC1 reveals non-association with hr-HPV16 and
an aggressive phenotype
Presence of hr-HPV16 was determined by assessing the level of
transcript of HPV16 E6 and E7 and expression of protein p16INK4a, a
surrogate marker for HPV [22]. Neither patient tumor nor VCC1 de-
rived from the tumor, expressed hr-HPV16 E6/E7 or p16INK4A (Fig. 3A
and B). Further, expression of several carcinogenesis-related genes was
profiled and illustrated here in the form of a heat map (Fig. 3C). VCC1
overexpressed VIM (two-folds), TWIST1 (three-folds) and expressed
CDH1 (five-folds) at a lower level when compared to NVK thus pointing
towards a more epithelial-mesenchymal transition (EMT)-like pheno-
type. In addition to this, several tyrosine kinases were overexpressed in
VCC1 (FGF2- four folds, PTK2- two folds and PDGFRβ-five folds). The
expression of cell cycle related genes was similar to NVK except for
CCND2 (decreased by five-folds). Of note, ITGA11, a gene encoding a
stromal cell-surface receptor for fibrillary collagens, was overexpressed
by three-folds in VCC1. In comparison, gene expression analysis of
UMSCV1A indicated a more angiogenic potential but less motile gen-
otype. UMSCV4 cells showed very few alterations except for lower
expression of VEGFA and VEGFC in comparison to NVK (Fig. 3C).
3.6. Engineered VCC1 3D models show invasive potential only in presence
of fibroblasts
In order to mimic the effect of fibroblasts on growth and differ-
entiation of cancer cells, we engineered 3D OTC. VCC1 showed little to
no invasion into the matrix in absence of fibroblasts (Fig. 4A b).
However, cancer cells invaded the matrix in presence of both NVF1 and
VCAF1 in the collagen matrix (Fig. 4A c, d). Histomorphometrical
analysis revealed no significant difference in the depth of invasion be-
tween NVF1 and VCAF1. Although VCAFs supported an increased in-
vasion (depth) of VCC1, the number of cancer cells invading into the
matrix was higher in NVF1 (Fig. S3). Histologically, the architecture
and the invasion pattern of engineered 3D OTC closely resembled that
of the native tumor tissue from which the cell line was derived (Fig. 4A
a). Immunohistochemistry revealed similar protein expression profile of
pan-cytokeratin (Fig. 4B a–d), vimentin (Fig. 4B e, g, h) and E-cadherin
(Fig. 4B i–l) across all 3D OTC. The protein expression for the marker of
proliferation, Ki-67 (Fig. 4B m, o, p) and of differentiation, involucrin
(Fig. 4B q, s, t) was similar when native tumor tissue and 3D OTC grown
with fibroblasts were compared. However, 3D OTC grown without fi-
broblasts displayed a thicker epithelium with higher degree of differ-
entiation but almost no proliferation (Fig. 4B r, n).
3.7. VCAF1 promotes invasive and tumorigenic potential of VCC1 in vivo
A take rate of 100% and an increase in tumor volume when com-
pared to VCC1 alone suggests that VCAF1 promoted tumorigenic po-
tential of VCC1 in mice xenografts. The histology of tumors formed
after injection of VCC1 alone was of SCC in nature but with no invasive
tumor fronts and with several cyst-like spaces (Fig. S2 B). In contrast,
the tumors formed after injection of VCC1 together with VCAF1 had
similar histology to the original tumor, both being well-differentiated
SCC (Fig. 5A a, b). Both the original tumor and VCC1-VCAF1 xenografts
had characteristic keratin pearl formation (Fig. 5B a, e) and invasive
single cell islands (Fig. 5B b, f). In addition, the xenografts showed local
muscular and perineural invasion similar to that observed in the ori-
ginal patient tumor (Fig. 5B c, d, g, h).
4. Discussion
Infrequent incidence of vulva squamous cell carcinoma associated
with lichen sclerosus et atrophicus compared to other female genital
cancers coupled with advanced age of patients has hampered genetic
and molecular studies on VLS-related tumorigenic pathways [23,24].
This has led to minimal improvement in treatment modalities in recent
decades [25]. With an estimated risk of 3–7% transformation of VLS to
VSCC, this inflammatory condition demands more preclinical models to
study the events in oncogenesis [11,26]. Cancer studies rely on the use
of cancer cell lines [27,28], xenografts [29,30], genetically modified
mice [30,31] and paraffin-embedded samples [32,33] as experimental
model systems. In vitro tumor cell lines represent valuable tools for
functional and mechanistic studies on cell processes involved in carci-
nogenesis [34], and a detailed characterization is fundamental before
application.
A thorough literature search identified nineteen cell lines derived
from squamous cell carcinoma of vulva [14,21,35,36]. Eleven of these
nineteen cell lines are derived from metastatic tumors, thus leaving
eight cell lines derived from primary, previously untreated tumors
[21,35,36]. Remarkably, none of the cell lines are derived from VLS-
VSCC, however this could be attributed to misdiagnosis and/or under
reporting [10,12]. Nonetheless, even in this context, the VCC1 cell line
isolated, established and characterized here, represents a novel and
unique model system to study VLS-VSCC. Confirmation that the cell line
was derived from corresponding tumor of the patient was provided by
STR DNA fingerprinting, which demonstrated 90% identical repeats.
The fact that they did not present a 100% match reflects the genomic
imbalances in the tumor and/or cell line. The present characterization
of VCC1 provides a make-up relevant for further studies on VLS-related
tumorigenesis. Not only did these cells show capacity to expand ex vivo
for more than 220 population doublings, they also showed (i) dis-
tinctive epithelial morphology with stem cell-like characteristics, (ii)
non-association with hr-HPV16 DNA, (iii) intermediate EMT pheno-
type, (iv) fibroblast dependent invasion in 3D OTC, and (v) in vivo tu-
morigenesis.
Unlimited proliferation and ability to self-renew confer ‘stemness’ to
cancer cells [37]. In this regard, we used colony and sphere formation
assay to evaluate stemness. VCC1 formed statistically more colonies
than well-established non VLS-VSCC cell lines reflective of enhanced
capacity for proliferation. In addition, VCC1 formed more spheres than
UMSCV4 but comparable to UMSCV1A. Besides to the number of
spheres formed, the size of the spheres could also be indicative of
higher tumorigenic potential. In the case of VCC1, both the size and
number of spheres was greater than UMSCV1A and UMSCV4. Another
point of interest is that VCC1 showed in vitro a predominantly holoclone
appearance, indicating an epithelial stem-cell phenotype [38].
In most solid tumors, EMT occurs at the invasive front imparting
migratory and invasive phenotype to the tumor cells. An important
characteristic of EMT is loss of epithelial markers (E-cadherin and
keratins), and upregulation of mesenchymal markers (vimentin, N-
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cadherin) and transcription factors (SNAIL1/2 and TWIST) [39]. In this
study, VCC1 showed increased expression of vimentin and Twist-1 and
decreased E-cadherin levels, indicating an EMT-like phenotype, how-
ever retaining cytokeratin expression. Combined, these results suggest
an intermediate EMT-like phenotype of VCC1 and supports the notion
that VLS-VSCC tumors have high metastatic potential [6].
3D OTC provides a reproducible and high-throughput assay mi-
micking the native epithelium in stratification, organization and cell-
cell interactions [38,40]. 3D OT models have a varied number of ap-
plications including drug screening prior to in vivo studies and deci-
phering the role of tumor stroma [13,38,41]. VCC1 showed little to no
invasion into the underlying collagen matrix in the absence of fibro-
blasts in 3D OTC. In contrast, VCC1 invaded the collagen matrix irre-
spective of the presence of normal or cancer-associated fibroblasts.
These results are in line with the study of Gaggioli et al. [42] and
studies done in our lab [13,41] where the importance of fibroblasts for
invasion of SCC cells has been well documented.
In spite of the immortal growth behavior of VCC1 in vitro, VCC1
alone failed to form continuously growing tumors in mice. This corro-
borates with previous findings using mice xenografts with UMSCV1A,
where this cell line did not form invasive tumors and failed to develop
continuously growing tumors [14]. However, VCC1 with VCAF1
formed continuously growing tumors suggesting that cancer-associated
fibroblasts can enhance the tumor-forming capability of VCC1 and
support their survival. In addition, the histology and local invasion
profile was similar between the original tumor and xenografts with
VCAFs but not with VCC1 alone. Taken together, both in 3D OTC and
xenografts models points to the key role of stromal fibroblasts in car-
cinogenesis of VLS-VSCC. Although, the investigation of tumor-stroma
cross talk is beyond the scope this study, we postulate that our novel
cell line VCC1, along with 3D OTC and xenograft models established
here will serve as the basis for further studies. Moreover, these 3D
models could serve as preclinical tools to determine changes associated
with the extracellular matrix in squamous cell carcinoma development
in the supra-adjacent epithelium. This could enhance our under-
standing of the tumor-stroma cross talk in inflammatory scarring skin
diseases such as VLS. In a longer perspective, this could be beneficial in
developing biomarkers, which can stratify patients with VLS having a
higher likelihood of evolving into VSCC.
In conclusion, we herein report the establishment of a novel cell
line, VCC1. It showed characteristic epithelial morphology with in-
creased stemness as well as migratory and invasive phenotypes than
already established VSCC cell lines. In addition, these cells are tu-
morigenic in vivo only when injected together with cancer-associated
fibroblasts suggesting a crucial role of fibroblasts in VLS-related onco-
genesis. Our findings suggest that this cell line could be beneficial in
Fig. 3. Detection of hr-HPV16 DNA and heatmap of genes involved in various oncogenic processes. A) Presence of hr-HPV16 E6 and E7 gene transcript was tested in
native tumor tissue, VCC1 and other VSCC cell lines using RT-qPCR. The PCR products were run on 1.5% agarose gel stained with ethidium bromide. UMSCV6 was
used as positive control. B) Immunohistochemistry of native patient tumor and VCC1 for p16INK4A was negative. Scale bar 100 μm. C) Heatmap of gene expression in
cancer cell lines. The names of cancer cell lines are listed on the top whereas the names of genes that were profiled are listed on the left of figure. A median expression
value was designated as black; red as decreased expression and green as increased expression compared to NVK. Results presented here were performed in triplicate
with each experiment performed further in duplicate. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of
this article.)
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elucidating the carcinogenesis of vulva cancer associated with lichen
sclerosus and the tumor-stroma cross talk.
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Fig. 4. Histology and immunohistochemistry of engineered vulvar cancer mucosa in comparison to native tissue. A) Representative images of H&E stained vulvar
cancer mucosa 3D OTC's grown without fibroblasts (b), with normal vulvar fibroblasts (c, NVF1) and cancer-associated fibroblasts (d, VCAF1) in comparison to tumor
tissue (a). B) Immunohistochemistry using antibodies against Pan-cytokeratin (a, b, c, d) (Pan-CK) was used to confirm the epithelial nature of cells in 3D OTCs.
Antibodies against vimentin (e, f, g, h) and E-cadherin (i, j, k, l) were used to study epithelial-mesenchymal transition and Ki-67 (m, n, o, p) and involucrin (q, r, s, t)
were used as markers of proliferation and differentiation respectively in native vulvar tumor tissue and 3D OTC grown with and without fibroblasts. Scale bar-100
μm.
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